S&P 500 Healthcare Sector SPDR (XLV)

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Cardinal Health has underperformed the S&P 500 Index over the past year, and analysts remain highly optimistic about the stock’s prospects.

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Though Centene has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Despite outperforming the broader market over the past year, Viatris continues to earn a cautiously optimistic outlook from Wall Street.

Although Medtronic has lagged behind the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

As Baxter International has notably underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.